These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Models for assessing the relationship between drug concentration and drug effect in performance horses. Kamerling SG; Owens JG Br Vet J; 1994; 150(6):507-25. PubMed ID: 7850442 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetic-pharmacodynamic modeling: time-dependent protein binding--an alternative interpretation of clockwise and counterclockwise hysteresis. Pedraz JL; Calvo B; Smithers JA; Thompson GA J Pharm Sci; 1992 Mar; 81(3):232-6. PubMed ID: 1640359 [TBL] [Abstract][Full Text] [Related]
45. A nonlinear feedback model capturing different patterns of tolerance and rebound. Gabrielsson J; Peletier LA Eur J Pharm Sci; 2007 Oct; 32(2):85-104. PubMed ID: 17689227 [TBL] [Abstract][Full Text] [Related]
46. Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model. Gentry WB; Krejcie TC; Henthorn TK; Shanks CA; Howard KA; Gupta DK; Avram MJ Anesthesiology; 1994 Aug; 81(2):316-24; discussion 25A. PubMed ID: 8053580 [TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Fujita T; Matsumoto Y; Kimura T; Yokota S; Sawada M; Majima M; Ohtani Y; Kumagai Y Br J Clin Pharmacol; 2002 Sep; 54(3):283-94. PubMed ID: 12236849 [TBL] [Abstract][Full Text] [Related]
49. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach. Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480 [TBL] [Abstract][Full Text] [Related]
50. Long-lasting rebound cue effects following single doses of nicotine and amphetamine: implications for understanding tolerance. Barrett RJ; Caul WF; Stadler JR; Smith RL Psychopharmacology (Berl); 2001 Oct; 157(4):349-57. PubMed ID: 11605093 [TBL] [Abstract][Full Text] [Related]
51. Integration of animal pharmacokinetic and pharmacodynamic data in drug safety assessment. Smith DA Eur J Drug Metab Pharmacokinet; 1993; 18(1):31-9. PubMed ID: 8335037 [TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects. Samtani MN; Perez-Ruixo JJ; Brown KH; Cerneus D; Molloy CJ J Clin Pharmacol; 2009 Mar; 49(3):336-50. PubMed ID: 19246731 [TBL] [Abstract][Full Text] [Related]
54. Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice. Krzyzanski W; Perez-Ruixo JJ; Harrold J J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):709-20. PubMed ID: 26341875 [TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Romberg R; Olofsen E; Sarton E; den Hartigh J; Taschner PE; Dahan A Anesthesiology; 2004 Jan; 100(1):120-33. PubMed ID: 14695733 [TBL] [Abstract][Full Text] [Related]
56. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys. Sun YN; Lee HJ; Almon RR; Jusko WJ J Pharmacol Exp Ther; 1999 Jun; 289(3):1523-32. PubMed ID: 10336548 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. Csajka C; Verotta D J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):227-79. PubMed ID: 16404503 [TBL] [Abstract][Full Text] [Related]
58. Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials. Ebling WF; Levy G Ann Pharmacother; 1996 Jan; 30(1):12-9. PubMed ID: 8773159 [TBL] [Abstract][Full Text] [Related]
59. Quantitative analysis of rate and extent of tolerance of biomarkers: application to nicotinic acid-induced changes in non-esterified fatty acids in rats. Ahlström C; Peletier LA; Gabrielsson J Eur J Pharm Sci; 2011 Oct; 44(3):250-64. PubMed ID: 21856416 [TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen. Trocóniz IF; Armenteros S; Planelles MV; Benítez J; Calvo R; Domínguez R Clin Pharmacokinet; 2000 Jun; 38(6):505-18. PubMed ID: 10885587 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]